Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase NA 1Phase 4 1

Status

Unknown 2Recruiting 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4Other hematologic neoplasm 4Gastrointestinal 4Breast 4Tumor-Agnostic 2Other solid neoplasm 2Gynecologic 2Sarcoma 1Myeloid 1Lymphoid 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Early Hormone Receptor-positive Breast Cancer 1

Interventions

Trastuzumab 696Paclitaxel 679Cyclophosphamide 634Docetaxel 554Capecitabine 467Letrozole 407Carboplatin 393Fulvestrant 379Doxorubicin 330Tamoxifen 288pembrolizumab 272Anastrozole 252Epirubicin 249exemestane 238pertuzumab 229Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 118

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Antineoplastic Agents × Breast × Clear all
NCT04004910 2022-03-24

A Study Comparing Immunopheresis® Alone or In Combination With Chemotherapy Versus Chemotherapy Alone in Treatment of Advanced Breast Cancer Patients

Immunicom Inc

Phase 1/2 Unknown
170 enrolled
Breast

Breast Neoplasms

NCT03591276 2020-10-23

KEYDOX

Shaare Zedek Medical Center

Phase 1/2 Recruiting
15 enrolled
Breast

Breast Neoplasms

NCT04278469 2020-02-20

Clinical High and Genomic Low Hormone Receptor-positive Early Breast Cancer Patients With or Without Adjuvant Chemotherapy

Gencurix, Inc.

Phase NA Recruiting
194 enrolled
Breast

Early Hormone Receptor-positive Breast Cancer

NCT03799679 2019-01-10

Albumin-Bound Paclitaxel Followed by Epirubicin in Combination With Cyclophosphamide in Triple Negative Breast Cancer

Fudan University

Phase 4 Unknown
60 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡